Summary by Futu AI
iBio Inc, a Delaware-based biotechnology company, filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on April 16, 2024. The filing pertains to the resale of up to 10,574,556 shares of common stock by selling stockholders, which includes shares acquired in a private placement transaction that closed on April 1, 2024. The private placement involved the sale of 2,701,315 outstanding shares of common stock, 2,585,963 shares issuable upon the exercise of pre-funded warrants, and 5,287,278 shares issuable upon the exercise of outstanding warrants, collectively known as the 'Selling Stockholders'. The registration statement is part of iBio's contractual obligations to facilitate the resale of these shares by the Selling Stockholders. iBio will not offer any shares under this prospectus and will not...Show More